Table 1.
Overview of structure, date of FDA approval and dosage frequency of diverse GLP-1 receptor agonists [154,155,156].
| Compound | Structure | FDA Approved | Dosage Frequency |
|---|---|---|---|
| Exenatide | Synthetic exendin-4, amino acid substitution at position 2 | 2005 | Twice daily |
| Lixisenatide | Based on exendin-4, amino acid substitution at position 2. Deletion of proline36 and C-terminally addition of a poly-lysine tail | 2016 | Once daily |
| Liraglutide | Acylated mammalian GLP-1 | 2010 | Once daily |
| Dulaglutide | Two stable GLP-1 moieties linked to an immunoglobulin fragment | 2014 | Once-weekly |
| Semaglutide | Acylated mammalian GLP-1, amino acid substitution at position 2. | Subcutaneous injection: 2017 Oral administration: 2019 |
Subcutaneous injection: once weekly Oral administration: once daily |